You are here: Home » News-CM » Companies » News
Business Standard

Lupin receives EIR for Pharmacovigilance inspection from the USFDA

Capital Market 

has received the Establishment Report (EIR) from the United States (USFDA) for the Post-marketing Adverse Drug Experience (PADE) inspection, indicating successful closure of the

The was conducted at Lupin's global group DSRM (Drug Safety & Risk Management) based out of between 14 January, 2019 and 18 January, 2019.

The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin's marketed products worldwide. The inspection closed with four observations.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, May 14 2019. 11:29 IST